JESDUVROQ

This brand name is authorized in United States.

Active ingredients

The drug JESDUVROQ contains one active pharmaceutical ingredient (API):

1	Daprodustat UNII JVR38ZM64B - DAPRODUSTAT
	Daprodustat is indicated for the treatment of anemia due to chronic kidney disease. Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC50 in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.
	Read more about Daprodustat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JESDUVROQ Film coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B03XA07		B Blood and blood forming organs → B03 Antianemic preparations → B03X Other antianemic preparations → B03XA Other antianemic preparations
Discover more medicines within B03XA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	0173-0897, 0173-0903, 0173-0906, 0173-0911, 0173-0914